Brilacidin

DB12997InvestigationalSmall molecule

Brilacidin is under investigation for the supportive care of Mucositis, Stomatitis, Mouth Diseases, and Head and Neck Neoplasms.

Mechanism: Pharmacologically active on Basement membrane-specific heparan sulfate proteoglycan core protein
Curator reviewed
Formula / weight: C₄₀H₅₀F₆N₁₄O₆ · 936.922 g/mol (avg)
Code names: PMX-30063 FREE BASE

Resolves to

Compound

Structure

NC(=N)NCCCCC(=O)NC1=CC(=CC(NC(=O)C2=CC(=NC=N2)C(=O)NC2=C(O[C@@H]3CCNC3)C(NC(=O)CCCCNC(N)=N)=CC(=C2)C(F)(F)F)=C1O[C@@H]1CCNC1)C(F)(F)F

Targets

What you can answer from here — as of September 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Brilacidin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.